26/02/2009
NOTIFICATION OF MAJOR INTEREST IN SHARES
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):
ReGen Therapeutics Plc
2. Reason for the notification:
An acquisition or disposal of voting rights
3. Full name of person(s) subject to the notification obligation (iii):
Andrew Clement Wilson
4. Full name of shareholder(s) (if difference from 3):
As Above
5. Date of the transaction and date on which the threshold is crossed or reached (v):
18th February 2009
6. Date on which issued notified:
25th February 2009
7. Threshold(s) that is/are crossed or reached:
13%-12%
8. Notified details
A: Voting rights attached to shares
Class/type of share if possible using the ISIN Code GB00B28XMY25
Situation Previous to the triggering transaction (vi) –
Number of Shares 2,110,750
Number of Voting Rights (viii) 2,110,750
Resulting situation after the triggering transaction (viii) –
Number of Shares 2,461,750
Number of Voting Rights – Direct (x) 2,461,750
Number of Voting Rights – Indirect (xi) N/A
% of voting rights – Direct 12.38
% of voting rights – Indirect N/A
B: Financial Instruments
Resulting situation after the triggering transaction (xii)
Type of financial instrument N/A
Expiration date (xiii) N/A
Exercise/Conversion Period/Date (xiv) N/A
Number of voting rights that may be acquired if the
instrument is exercised/converted N/A
% of voting rights N/A
Total (A+B)
Number of voting rights 2,461,750
% of voting rights 12.38
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv): Giltspur Nominees Limited-Brewin Dolphin
Proxy Voting:
10. Name of the proxy holder: N/A
11. Number of voting rights proxy holder will cease to hold: N/A
12. Date on which proxy holder will cease to hold voting rights: N/A
13. Additional information: Brewin Dolphin Act As
Broker
14. Contact name: Stephen Cartwright
15. Contact telephone number: 028 90 446000
0845 213 4014
For further information:
For further information, please contact:
Percy Lomax
ReGen Therapeutics Plc
Tel: 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel: 020 7628 3396